China Resources Sanjiu Medical & Pharmaceutical (000999) Fundamentals 2026 — P/E 12.8x, Revenue Analysis | SniperIQ
China Resources Sanjiu Medical & Pharmaceutical (000999) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥41.9B, trading at ¥25.16 on the SHZ. This SniperIQ fundamentals page covers China Resources Sanjiu Medical & Pharmaceutical's valuation (P/E 12.8x, P/B 1.4x), profitability (net margin 9.9%), revenue (¥31.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is China Resources Sanjiu Medical & Pharmaceutical's market cap?
China Resources Sanjiu Medical & Pharmaceutical (000999) has a market capitalization of approximately ¥41.9B, trading at ¥25.16 on the SHZ. Market cap moves with the live share price.
What is China Resources Sanjiu Medical & Pharmaceutical's P/E ratio?
China Resources Sanjiu Medical & Pharmaceutical's trailing twelve-month P/E ratio is 12.8x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is China Resources Sanjiu Medical & Pharmaceutical?
China Resources Sanjiu Medical & Pharmaceutical runs a net profit margin of 9.9%, a gross margin of 94.0%, and an operating margin of 14.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does China Resources Sanjiu Medical & Pharmaceutical generate?
China Resources Sanjiu Medical & Pharmaceutical reported revenue of ¥31.6B for fiscal year 2025, with net income of ¥3.4B and earnings per share (EPS) of 2.06. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does China Resources Sanjiu Medical & Pharmaceutical pay a dividend?
China Resources Sanjiu Medical & Pharmaceutical offers a trailing dividend yield of about 4.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is China Resources Sanjiu Medical & Pharmaceutical financially healthy?
China Resources Sanjiu Medical & Pharmaceutical carries a debt-to-equity ratio of 0.28x and a current ratio of 2.03x, with a market beta of 0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is China Resources Sanjiu Medical & Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China Resources Sanjiu Medical & Pharmaceutical (000999) the key facts are: market cap ¥41.9B, P/E 12.8x, revenue ¥31.6B, 52-week range 21.6-32.59. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track China Resources Sanjiu Medical & Pharmaceutical's full fundamentals live
Get China Resources Sanjiu Medical & Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.